Apretude Cost Per Month

“Cost” means two very different things here: the manufacturer’s list price, and what you actually pay after insurance and assistance programs. The table shows both, alongside every FDA-approved PrEP option, so you can compare honestly.

The gap between Apretude’s terrifying list price and the $0 most patients pay is where all the confusion lives. These answers walk through the real numbers, the dosing schedule, how it stacks up against the alternatives, and the safety nets for people without insurance.

• 1
  How much does Apretude cost per month? List price: ~$1,900–$2,100/month of protection (~$3,700–$4,100 per every-2-month shot) · Most insured patients: $0 · Uninsured patients may qualify for it completely free

  Apretude isn’t priced monthly because it isn’t taken monthly — each 600 mg injection covers two months of protection, and pharmacy pricing puts a single vial at roughly $3,700 to $4,100 before insurance, which averages out to about $1,900–$2,100 per month. Across a first year (seven injections including the two starter doses) the list-price total lands between $22,000 and $29,000; subsequent years with six injections run around $22,000–$25,000. Now the part the sticker price hides: because PrEP carries an “A” recommendation from the U.S. Preventive Services Task Force, the Affordable Care Act requires most private insurance plans and Medicaid expansion programs to cover it with no copay, no coinsurance, and no deductible. Medicare also covers PrEP — including injectable administration — without cost-sharing under Part B. For people whose plans impose costs anyway, the manufacturer’s copay program can cover up to $7,500 per year, and an income-based patient assistance program supplies the drug free to those who qualify. The honest summary: the list price is what insurers and the manufacturer argue about; the large majority of patients who pursue the available pathways pay nothing or close to it.
• 2
  How much does Apretude cost a year? List price: ~$22,000–$29,000 first year (7 shots) · ~$22,000–$25,000 ongoing years (6 shots) · With insurance + assistance: typically $0 for the drug itself · Budget separately for visit and lab charges if your plan applies them

  Year one is the most expensive on paper because the schedule front-loads injections: a starter shot, a second shot one month later, then one every two months — seven total. From year two onward it settles at six injections annually. At list price that’s $22,000–$29,000 the first year, but virtually nobody pays retail: insured patients are protected by the preventive-services rules, and the combination of copay assistance and the free-medication program catches most others. What can generate real out-of-pocket costs across a year isn’t usually the drug — it’s the wrapper around it: office visit charges for each injection appointment, the required HIV test before every shot, and periodic kidney and STI labs. Federal guidance says ancillary services essential to PrEP should also be covered without cost-sharing, and Medicare explicitly covers the injections, HIV testing, and up to eight counseling visits a year at no charge — but commercial plans don’t always code these correctly. Practical move: before your first appointment, ask the clinic two questions — “Will the drug be billed through medical or pharmacy benefit?” and “Will my labs and injection visits be billed as preventive?” Getting those answers up front prevents nearly all of the surprise bills people report.
• 3
  Is Apretude every 2 months — how does the schedule work? Yes: 2 starter shots one month apart, then 1 injection every 2 months · Optional 1-month oral lead-in pill first · 7-day grace window if you must reschedule · Missing longer requires calling your provider promptly

  The maintenance rhythm is one injection every two months — six appointments a year, each a quick visit where a clinician gives the shot in the buttock muscle and runs a rapid HIV test first. Getting there involves a short on-ramp: two initiation injections given one month apart, and some providers offer (or patients choose) a month of daily oral cabotegravir tablets beforehand to confirm the medication is well tolerated before committing to a long-acting shot. The schedule has some built-in flexibility — appointments can shift up to seven days either direction without breaking protection — but discipline matters beyond that window, because drug levels decline slowly and unevenly. That slow decline is also why stopping deserves planning rather than simply not showing up: cabotegravir can linger in the body at low, non-protective levels for a year or more after the last injection (the so-called pharmacologic tail), and during that stretch you’re not protected but exposure could, in rare cases, lead to infection with resistance complications. Anyone discontinuing should talk with their provider about bridging to daily oral PrEP. For people weighing the commitment: six short appointments a year versus 365 chances to forget a pill is precisely the trade that made the injection outperform daily pills in trials.
• 4
  How much does a 30-day supply of Truvada cost — and how does it compare? Generic Truvada: roughly $30–$60/month retail, often under $30 with discount cards, $0 with most insurance · Brand-name Truvada: ~$2,000+/month · The generic is the budget champion of PrEP by a wide margin

  Since the patent expired, generic Truvada (emtricitabine/tenofovir disoproxil fumarate) has become remarkably cheap: cash prices at major pharmacies commonly run $30–$60 for a 30-day supply, discount cards push it lower still, and insured patients owe $0 under the same preventive-services rules that cover Apretude. The brand-name version still lists above $2,000/month, which is why essentially everyone uses the generic. So why would anyone choose a $22,000-list-price injection over a $30 pill? One reason, and it’s not trivial: the pill only works if you take it, every day, indefinitely. Real-world adherence is the Achilles’ heel of oral PrEP — and in the large head-to-head trials, people randomized to the cabotegravir injection had meaningfully fewer HIV infections than those on daily pills, not because the molecule is stronger but because every-two-month dosing removes human forgetfulness from the equation. The cost-effectiveness question, in other words, is personal: if you take a daily pill reliably, generic oral PrEP delivers excellent protection for pocket change. If pills get missed — travel, privacy concerns at home, an unpredictable schedule, or simple pill fatigue — the injection’s higher system cost buys protection that actually happens, and your insurer, not you, typically absorbs the difference.
• 5
  Is Apretude worth it — how effective is it? In major trials, the injection beat daily oral PrEP — roughly 66–89% fewer infections than pill takers, who were already well protected · Best fit: anyone for whom a daily pill is the weak link · Requires showing up 6 times a year

  “Worth it” has two parts — effectiveness and fit — and the effectiveness evidence is unusually strong. In the two landmark trials that earned its approval, covering thousands of participants across multiple continents and populations, people receiving cabotegravir injections acquired HIV substantially less often than people assigned to daily oral PrEP: the injection arm showed about 66% fewer infections in one trial (men who have sex with men and transgender women) and 89% fewer in the other (cisgender women) — a superiority result, not just equivalence, against a comparator that already works very well when taken faithfully. The catch is that the injection’s advantage came almost entirely from adherence: pills fail when they sit in the bottle. So the fit question becomes: which failure mode describes you? If a daily pill is genuinely easy for you, oral PrEP is highly protective and the injection adds convenience more than protection. If pills get skipped — or if having a pill bottle at home creates privacy or safety concerns, a reality for many — the injection is arguably the most reliable HIV prevention ever brought to market. Side effects are mostly injection-site soreness for a few days, with weight gain, headache, and fever occurring in a minority. The commitment it asks in return: six clinic visits a year, on time, and a planned exit if you ever stop.
• 6
  How do I get Apretude for free or close to it? Insured: ACA preventive rules mean $0 for most · Plan still charging? Manufacturer copay assistance covers up to $7,500/year · Uninsured/underinsured: ViiVConnect patient assistance provides it free based on income · Community clinics & Ready, Set, PrEP fill remaining gaps

  There’s a ladder of programs, and almost everyone lands on a rung. Rung one: insurance. Most private plans, Medicaid expansion programs, and Medicare must cover PrEP without cost-sharing, so the correct out-of-pocket for the drug is $0 — if your explanation of benefits shows otherwise, that’s frequently a coding error worth appealing rather than a true denial. Rung two: the manufacturer’s savings program (ViiVConnect), which can cover up to $7,500 per year of copays and coinsurance for commercially insured patients whose plans impose costs — enough to zero out nearly any cost-share. Rung three: for the uninsured and underinsured, the same ViiVConnect umbrella runs an income-based patient assistance program that ships the medication free of charge to qualifying patients. Rung four: the federal Ready, Set, PrEP program and the national network of community health centers, Ryan White clinics, and local health departments, which provide PrEP services — including the labs and visits that programs above don’t always cover — on sliding-fee scales that can reach $0. The practical path: call ViiVConnect at 1-844-588-3288 or visit viivconnect.com before assuming you can’t afford it, and ask any sexual-health clinic near you about their PrEP navigation services — navigators do this paperwork daily and dramatically shorten the process.
• 7
  Apretude vs. Descovy vs. the new twice-yearly shot — which makes sense? Descovy: daily pill, brand-priced, not approved for everyone · Apretude: every 2 months, widely covered now · Yeztugo: every 6 months, impressive trial results, but insurance coverage still catching up · Availability and coverage often decide

  All three beat no protection by a mile, so the real comparison is logistics and coverage. Descovy is a daily brand-name pill (list price above $2,200/month) positioned as gentler on kidneys and bone markers than older oral PrEP; note it isn’t approved for people whose exposure risk comes from receptive vaginal sex, which excludes a large population, and with generic Truvada nearly free, many insurers steer pill users there first. Apretude owns the middle ground: every-two-month dosing, superiority data against daily pills, and — crucially right now — established insurance coverage under the preventive-services mandate, plus a mature assistance-program safety net. Yeztugo (lenacapavir) is the newest arrival and the headline-maker: one injection under the skin every six months, with trial results of 96–100% protection that earned it major scientific accolades and a fresh CDC recommendation. Its weakness today is purely administrative — at $28,218/year list, some major insurers and pharmacy-benefit managers have been slow to add it, with at least one large PBM excluding it from commercial formularies for now, and because the latest preventive-services recommendation predates its approval, plans have wiggle room on $0 coverage. The pragmatic answer many clinicians give: take the longest-acting option your insurance actually covers today, and revisit annually — this market is moving quickly in patients’ favor.
• 8
  What side effects should I budget for — medically and financially? Most common: injection-site pain/swelling for a few days (very common, fades with subsequent shots) · Less common: headache, fever, fatigue, weight gain · Serious reactions are rare · Required monitoring (HIV tests, periodic labs) should be billed as preventive

  The dominant side effect is exactly what you’d expect from a 3 mL intramuscular injection: soreness, swelling, or a firm knot at the injection site, affecting a large majority of patients after early doses and typically fading within a few days — most people report it diminishes with successive injections as the body adjusts. A smaller share experience headache, fever, fatigue, muscle aches, sleep disturbance, or modest weight gain. Serious problems — hypersensitivity reactions, liver enzyme elevations, significant mood changes — are uncommon but are the reason an optional month of oral cabotegravir tablets exists: it lets you test-drive the molecule with something you can simply stop taking, before receiving a long-acting shot that stays in your system for months. Financially, the side-effect budget is mostly about the monitoring wrapper: an HIV test is mandatory before every injection (a positive test while on PrEP changes treatment decisions immediately), and periodic broader labs are standard. Under federal preventive-coverage guidance these ancillary services should carry no cost-sharing alongside the drug, and Medicare’s PrEP benefit explicitly bundles testing and counseling at $0 — but miscoded claims happen, so review each explanation of benefits. Report any concerning reaction to your provider, and side effects can also be reported to the FDA’s MedWatch program at 1-800-332-1088.

Use the buttons below to find PrEP-prescribing clinics, sexual-health and community health centers, and pharmacies near you. The official national locator at locator.hiv.gov filters specifically for PrEP services and assistance programs.